IgA Nephropathy clinical trials at UCSF

2 research studies open to eligible people

Showing trials for

  • BION-1301 in Adults With IgA Nephropathy

    open to eligible people ages 18 years and up

    Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

    San Francisco, California and other locations

  • Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

    open to eligible people ages 18 years and up

    The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.

    San Francisco, California and other locations

Last updated: